Anti-mullerian Hormone in Acute Lymphoblastic Leukemia

IRCCS Burlo Garofolo

Status: Enrolling

Conditions: Acute Lymphoblastic Leukemia

Study type: Observational

Funder types: Other

Identifiers

NCT05793463

RC 03/17

Details and patient eligibility

About

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with current survival rates exceeding 90%. As cure rates improve, increasing attention is focused on survivor quality of life, including fertility. It is generally accepted that cancer treatments in childhood may interfere with gonadal function, reducing the pool of primordial follicles and consequently causing premature menopause in women. Anti-Mullerian hormone (AMH) levels is a valuable quantitative indicator of ovarian reserve, being directly related to the number of antral follicles. The evaluation of this hormone makes it possible to identify women at risk of early menopause and to propose them interventions for monitoring and preservation of oocytes, allowing girls to be able to have children once they reach adulthood. The objective of this study is to determine ovarian reserve in girls with ALL before and after treatment by means of the evaluation of the AMH assay.

Enrollment: 10 estimated patients

Sex: Female

Ages: 1 month to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female less than 18 years of age
• Diagnosis of acute lymphoblastic leukemia
• enrollment within the first month after diagnosis

Exclusion criteria

• Previous treatments with cytostatics drugs
• ALL as a second malignancy
• Syndromic patient or primary hypogonadism